Overview

Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation

Status:
Not yet recruiting

Trial end date:
2022-08-01

Target enrollment:

Participant gender:

Summary

Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) designed to directly block the interaction between PD-1 and its ligands and enable the T cell to remain active and co-ordinate an attack on tumor cells. We hypothesise that the Clinical Benefit Rate (CBR) and progression free survival (PFS) of metastatic breast cancer patients who have ESR1 mutation will improve following administration of a combination of pembrolizumab and tamoxifen.

Phase:

Phase 2

Details

Lead Sponsor:

Mediclinic Middle East

Treatments:

Hormones
Pembrolizumab
Tamoxifen